|
children |
56 |
|
chinese |
54 |
|
covid-19 |
47 |
|
humans |
41 |
|
male |
30 |
|
female |
29 |
|
child |
27 |
|
adolescent |
26 |
|
adult |
22 |
|
child, preschool |
21 |
|
magnetic resonance imaging |
18 |
|
bone marrow transplantation |
16 |
|
cancer |
16 |
|
child psychosocial problems |
16 |
|
coronavirus |
16 |
|
cytokines |
16 |
|
healthcare workers |
16 |
|
home confinement |
16 |
|
hospital policies |
16 |
|
infant |
16 |
|
perceived stress |
16 |
|
psychological wellbeing |
16 |
|
school closure |
16 |
|
infants |
15 |
|
medical sciences |
15 |
|
immunoglobulin |
13 |
|
immunotherapy |
13 |
|
lymphocyte subsets |
13 |
|
quality of life |
13 |
|
sars |
13 |
|
adolescents |
12 |
|
asparaginase |
12 |
|
convalescence |
12 |
|
false positive |
12 |
|
fatal outcome |
12 |
|
fatigue |
12 |
|
kawasaki disease |
12 |
|
sars-cov-2 |
12 |
|
sars-cov-2 rbd igg |
12 |
|
serology |
12 |
|
t cell response |
12 |
|
allergy |
11 |
|
epidemiology |
11 |
|
leukemia |
11 |
|
neurotoxicity |
11 |
|
pediatric |
11 |
|
physical activity |
11 |
|
asia |
10 |
|
brain microstructure |
10 |
|
chemotherapy |
10 |
|
cognition |
10 |
|
diffusion kurtosis imaging |
10 |
|
functional outcome |
10 |
|
human leukocyte antigens |
10 |
|
hypersensitivity |
10 |
|
intracranial germ cell tumor |
10 |
|
mesenchymal stem cells |
10 |
|
molecular tumour board |
10 |
|
neurotoxicity syndromes |
10 |
|
next-generation sequencing |
10 |
|
oncology |
10 |
|
precision oncology |
10 |
|
radiation therapy |
10 |
|
sequence-directed therapy |
10 |
|
t-lymphocytes |
10 |
|
age-stratified |
9 |
|
alleles |
9 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
9 |
|
diffusion |
9 |
|
germ cells |
9 |
|
hematopoietic stem cell transplantation |
9 |
|
inflammation |
9 |
|
radiotherapy |
9 |
|
travel history |
9 |
|
vaccine |
9 |
|
abdominal pain |
8 |
|
adolescence |
8 |
|
antimicrobial resistance |
8 |
|
bacteria |
8 |
|
bnt162b2 mrna covid-19 vaccines |
8 |
|
childhood cancer |
8 |
|
childhood cancer survivors |
8 |
|
diagnosis, differential |
8 |
|
diarrhoea |
8 |
|
hong kong |
8 |
|
hong kong - epidemiology |
8 |
|
hypercytokinemia |
8 |
|
in situ hybridization, fluorescence |
8 |
|
innate immunity |
8 |
|
kir genetics |
8 |
|
meningitis |
8 |
|
neonates |
8 |
|
neuroblastoma |
8 |
|
nk cells |
8 |
|
paediatric gastroenterology |
8 |
|
phenotype |
8 |
|
self-esteem |
8 |
|
thalassemia |
8 |
|
translation to patients |
8 |
|
treatment outcome |
8 |
|
vaccine-related myocarditis |
8 |
|
brain tumors |
7 |
|
cells, cultured |
7 |
|
china |
7 |
|
chinese children |
7 |
|
combined modality therapy |
7 |
|
cord blood transplantation |
7 |
|
early childhood exposure |
7 |
|
family financial pressure |
7 |
|
graft survival |
7 |
|
health-related quality of life |
7 |
|
immune thrombocytopenia |
7 |
|
immunological profiles |
7 |
|
immunophenotyping |
7 |
|
karyotyping |
7 |
|
middle aged |
7 |
|
nursing |
7 |
|
oncology medical sciences |
7 |
|
pediatrics |
7 |
|
post-transplantation lymphoproliferative disease |
7 |
|
primitive neuroectodermal tumor |
7 |
|
recurrence |
7 |
|
retrospective studies |
7 |
|
saliva |
7 |
|
solid organ transplantation |
7 |
|
telomere |
7 |
|
transplantation |
7 |
|
viral load |
7 |
|
25(oh)d |
6 |
|
anaphylaxis |
6 |
|
asthma |
6 |
|
basal ganglia |
6 |
|
biomarkers |
6 |
|
bone marrow aspiration |
6 |
|
cancer-related fatigue |
6 |
|
cfu-f |
6 |
|
challenge |
6 |
|
depressive symptoms |
6 |
|
drug |
6 |
|
extracellular vesicle |
6 |
|
gc gene |
6 |
|
head and neck neoplasms |
6 |
|
hepatoblastoma |
6 |
|
infection |
6 |
|
mesenchymal stromal cell |
6 |
|
microfluidics |
6 |
|
microrna |
6 |
|
molecular genetics |
6 |
|
neurofibromatosis |
6 |
|
pediatric cardiology |
6 |
|
prognosis |
6 |
|
quantitative phase imaging |
6 |
|
rhinitis |
6 |
|
self-efficacy |
6 |
|
single-cell imaging |
6 |
|
single‐cell imaging |
6 |
|
snoring |
6 |
|
telomere length |
6 |
|
tomography, x-ray computed |
6 |
|
translocation, genetic |
6 |
|
transplantation, homologous |
6 |
|
tumor |
6 |
|
tumor microenvironment |
6 |
|
ultrafast imaging |
6 |
|
vdr gene |
6 |
|
ventricular function |
6 |
|
vitamin d-binding protein |
6 |
|
γδ-t cells |
6 |
|
acute graft-versus-host disease |
5 |
|
alport's syndrome |
5 |
|
beta-thalassemia - blood - immunology - therapy |
5 |
|
beta-thalassemia - genetics |
5 |
|
cancer survivors |
5 |
|
cancer treatment |
5 |
|
candida |
5 |
|
case report |
5 |
|
case-control studies |
5 |
|
cd55 |
5 |
|
childhood lymphoma |
5 |
|
chromosomes, human, pair 1 - genetics |
5 |
|
chromosomes, human, pair 9 - genetics |
5 |
|
cohort studies |
5 |
|
complement |
5 |
|
cord blood |
5 |
|
cord blood stem cell |
5 |
|
cranial irradiation |
5 |
|
craniopharyngioma |
5 |
|
deferiprone (l1) |
5 |
|
disease progression |
5 |
|
esophageal leiomyoma |
5 |
|
ferritins - blood |
5 |
|
fetal blood |
5 |
|
fetal hemoglobin |
5 |
|
fetal hemoglobin - biosynthesis |
5 |
|
fetal tissue transplantation |
5 |
|
graft versus host disease |
5 |
|
histocompatibility testing |
5 |
|
hmsc |
5 |
|
hmsc transplantation |
5 |
|
human mesenchymal stem cells |
5 |
|
human mesenchymal stromal cells |
5 |
|
human t cell |
5 |
|
humanized mice |
5 |
|
imaging flow cytometry |
5 |
|
intracranial germ cell tumors |
5 |
|
iron overload |
5 |
|
label-free biophysical phenotyping |
5 |
|
methotrexate |
5 |
|
neurocognitive function |
5 |
|
nucleic acid amplification |
5 |
|
outcome |
5 |
|
pd-1/programmed death-ligand 1 |
5 |
|
pediatric oncology |
5 |
|
performance status |
5 |
|
pericardial effusion |
5 |
|
polymerase chain reaction |
5 |
|
precursor cell lymphoblastic leukemia-lymphoma - diagnosis - drug therapy - genetics |
5 |
|
pulmonary fibrosis |
5 |
|
rampant caries |
5 |
|
remission induction |
5 |
|
renal abscess |
5 |
|
sex chromosome aberrations - diagnosis - genetics |
5 |
|
silver diamine fluoride |
5 |
|
survivors |
5 |
|
thrombocytopenia |
5 |
|
tretinoin - therapeutic use |
5 |
|
ultrafast single cell imaging |
5 |
|
β-thalassemia |
5 |
|
β-thalassemia major |
5 |
|
11c-acetate |
4 |
|
acute disease |
4 |
|
adenoviridae - physiology |
4 |
|
adiposity |
4 |
|
alloimmune tolerance |
4 |
|
alpha-thalassemia - blood - complications - therapy |
4 |
|
animals |
4 |
|
anti-bacterial agents - therapeutic use |
4 |
|
antineoplastic combined chemotherapy protocols - administration & dosage |
4 |
|
apoptosis |
4 |
|
ascites - etiology |
4 |
|
asian continental ancestry group |
4 |
|
autoimmune diseases |
4 |
|
autoimmune diseases - epidemiology - ethnology |
4 |
|
bacterial infections - epidemiology - ethnology |
4 |
|
bioimprinting |
4 |
|
biological markers |
4 |
|
biomimetic material |
4 |
|
bk virus - physiology |
4 |
|
blood smear |
4 |
|
blood transfusion - adverse effects |
4 |
|
bone marrow examination |
4 |
|
bone marrow examination - methods |
4 |
|
bone marrow transplantation - pathology |
4 |
|
brain tumor |
4 |
|
brain tumor ;;; suvivors |
4 |
|
carcinoma, hepatocellular - epidemiology - pathology |
4 |
|
cell culture techniques - methods |
4 |
|
cell-free dna |
4 |
|
central venous catheter |
4 |
|
chemokine cxcl10 - metabolism |
4 |
|
childhood all |
4 |
|
chimera |
4 |
|
chromosome aberrations |
4 |
|
chronic |
4 |
|
circulating dna |
4 |
|
clinical article |
4 |
|
coculture techniques |
4 |
|
combined therapy |
4 |
|
complication |
4 |
|
complications |
4 |
|
confirmatory factor analysis |
4 |
|
congenital fibrosarcoma |
4 |
|
cyclosporin |
4 |
|
cytogenetics |
4 |
|
depression symptoms |
4 |
|
desferrioxamine (dfo) |
4 |
|
dna fingerprinting |
4 |
|
dna methylation |
4 |
|
donor lymphocyte infusion |
4 |
|
ewing sarcoma |
4 |
|
filipino (citizen) |
4 |
|
follow-up studies |
4 |
|
frequency haplotypes |
4 |
|
gadolinium dtpa - diagnostic use |
4 |
|
genotype |
4 |
|
germ cell tumor |
4 |
|
globins - genetics |
4 |
|
graft versus tumor effect |
4 |
|
granulocytes |
4 |
|
haploidentical |
4 |
|
haploidentical hematopoietic stem cell transplantation |
4 |
|
hb bart's disease |
4 |
|
health promotion |
4 |
|
health resources |
4 |
|
hematopoietic stem cell transplantation - adverse effects - methods |
4 |
|
hemoglobin f |
4 |
|
hemoglobinopathies - blood - complications - therapy |
4 |
|
hemoglobins, abnormal |
4 |
|
hepatic artery ligation |
4 |
|
hepatoblastoma - epidemiology - pathology |
4 |
|
heterozygote |
4 |
|
histocompatibility - immunology |
4 |
|
hla antigens |
4 |
|
hla mismatched |
4 |
|
hla-dr antigens |
4 |
|
hospitalization - statistics & numerical data |
4 |
|
human leukocyte antigen |
4 |
|
imaging systems |
4 |
|
immunoglobulins |
4 |
|
immunologic factors - pharmacology |
4 |
|
immunology |
4 |
|
infant, newborn |
4 |
|
intestinal |
4 |
|
intestinal mucosa - pathology |
4 |
|
intestinal neoplasms - pathology - radiography |
4 |
|
intestine, small - pathology - radiography |
4 |
|
iron - analysis |
4 |
|
iron chelating agents - therapeutic use |
4 |
|
jmml |
4 |
|
klebsiella infections - complications - drug therapy - epidemiology |
4 |
|
klebsiella pneumoniae - drug effects |
4 |
|
leukocytes, mononuclear |
4 |
|
leukoencephalopathy |
4 |
|
linitis plastica - complications - diagnosis |
4 |
|
liver neoplasms - epidemiology - pathology |
4 |
|
liver tumors |
4 |
|
lymphocyte depletion |
4 |
|
major histocompatibility complex (mhc) |
4 |
|
matching probability |
4 |
|
medical and biological imaging |
4 |
|
medulloblastoma |
4 |
|
megakaryocytes - pathology |
4 |
|
metastasis |
4 |
|
microscopy |
4 |
|
microspheres |
4 |
|
mixed chimerism |
4 |
|
muscle strength |
4 |
|
neoplasms, multiple primary - diagnosis - pathology - therapy |
4 |
|
neural crest |
4 |
|
neuroectodermal tumors, primitive, peripheral - diagnosis - pathology - therapy |
4 |
|
neurofibromatosis 1 - diagnosis - pathology - therapy |
4 |
|
neurological complications |
4 |
|
neutropenia |
4 |
|
neutropenia - epidemiology - ethnology |
4 |
|
noninherited maternal antigen |
4 |
|
nuclear family |
4 |
|
obesity |
4 |
|
paediatric patients with cancer |
4 |
|
panax - chemistry |
4 |
|
pediatric cancer |
4 |
|
pelvis - pathology |
4 |
|
physical activity self-efficacy |
4 |
|
plant extracts - pharmacology |
4 |
|
positron emission tomography |
4 |
|
posterior reversible encephalopathy syndrome |
4 |
|
precursor cell lymphoblastic leukemia-lymphoma - drug therapy |
4 |
|
precursor cell lymphoblastic leukemia-lymphoma - genetics |
4 |
|
primary immunodeficiencies |
4 |
|
primary liver tumours |
4 |
|
psychological well-being |
4 |
|
purpura, thrombocytopenic, idiopathic - drug therapy - etiology |
4 |
|
qualitative |
4 |
|
rare tumor |
4 |
|
registry/registry analysis |
4 |
|
regulatory t cell |
4 |
|
relapse |
4 |
|
resource needs |
4 |
|
rhabdomyosarcoma |
4 |
|
rhabdomyosarcoma - mortality - pathology - therapy |
4 |
|
risk factors |
4 |
|
sarcoma, ewing - pathology - radiography |
4 |
|
sensitivity and specificity |
4 |
|
severe combined immunodeficiency |
4 |
|
severe combined immunodeficiency - pathology - therapy |
4 |
|
severity |
4 |
|
signal transduction - drug effects |
4 |
|
small intestine |
4 |
|
soft tissue neoplasms - mortality - pathology - therapy |
4 |
|
standard of care |
4 |
|
statistics, nonparametric |
4 |
|
stem cell |
4 |
|
stem cell transplantation - adverse effects |
4 |
|
stomach neoplasms - complications - diagnosis |
4 |
|
survival analysis |
4 |
|
tendon |
4 |
|
teratoma |
4 |
|
thalassaemia |
4 |
|
thalassemia - complications |
4 |
|
tissue engineering - methods |
4 |
|
tissue microenvironment |
4 |
|
total body irradiation |
4 |
|
transarterial embolization |
4 |
|
transplant-related morbidity |
4 |
|
transplantation, homologous - adverse effects - immunology - methods |
4 |
|
tumor rupture |
4 |
|
ultrafast technology |
4 |
|
urinary tract infections - diagnosis - urine - virology |
4 |
|
virus activation |
4 |
|
x chromosome |
4 |
|
y chromosome |
4 |
|
12) (q11 |
3 |
|
5-ht3 receptor antagonist |
3 |
|
acinic cell carcinoma |
3 |
|
acute leukaemia |
3 |
|
acute promyelocytic leukaemia |
3 |
|
administration, oral |
3 |
|
adrenal gland |
3 |
|
adrenal gland neoplasms - diagnosis |
3 |
|
aged |
3 |
|
all |
3 |
|
all-trans retinoic acid |
3 |
|
alpha-thalassemia |
3 |
|
american college students |
3 |
|
aml1 amplification |
3 |
|
anaerobic salmonella |
3 |
|
anaplastic lymphoma (間變性淋巴瘤) |
3 |
|
anemia |
3 |
|
anisotropy |
3 |
|
antenatal screening |
3 |
|
antiemetic |
3 |
|
antineoplastic agents - therapeutic use |
3 |
|
aplastic anaemia |
3 |
|
apoptosis - drug effects |
3 |
|
apoptosis - immunology |
3 |
|
apoptotic cells |
3 |
|
arsenicals - administration & dosage |
3 |
|
arsenicals - therapeutic use |
3 |
|
arthritis, rheumatoid - immunology - metabolism |
3 |
|
artificial gene fusion |
3 |
|
asian |
3 |
|
asparaginase - adverse effects |
3 |
|
autoimmune disease |
3 |
|
autologous |
3 |
|
bacterial toxins - pharmacology |
3 |
|
beta-thalassemia |
3 |
|
beta-thalassemia - complications - physiopathology - radiography |
3 |
|
beta-thalassemia - drug therapy - metabolism - therapy |
3 |
|
biopsy |
3 |
|
blood platelets - drug effects - radiation effects |
3 |
|
bone (骨) |
3 |
|
bone and bones - physiology |
3 |
|
bone marrow cells - pathology |
3 |
|
bone neoplasms - drug therapy - epidemiology - pathology - surgery |
3 |
|
bone regeneration - physiology |
3 |
|
brain - pathology |
3 |
|
brain - radiation effects |
3 |
|
brain damage, chronic - diagnosis - etiology |
3 |
|
brain mapping |
3 |
|
brain neoplasms - drug therapy - pathology |
3 |
|
brain neoplasms - radiotherapy |
3 |
|
brain stem - radiation effects |
3 |
|
breast neoplasms - secondary |
3 |
|
cancer chemotherapy |
3 |
|
cancer epidemiology |
3 |
|
cancer incidence |
3 |
|
carcinoma - genetics - pathology |
3 |
|
caries |
3 |
|
catheterization, central venous |
3 |
|
cd4-positive t-lymphocytes - immunology - metabolism |
3 |
|
cell delivery |
3 |
|
cell differentiation |
3 |
|
cell differentiation - drug effects - physiology |
3 |
|
cell differentiation - immunology |
3 |
|
cell proliferation - drug effects |
3 |
|
central venous catheter blockage |
3 |
|
cerebellar neoplasms - diagnosis - drug therapy - radiotherapy |
3 |
|
cerebellar neoplasms - drug therapy - radiotherapy - surgery |
3 |
|
cerebellar neoplasms - pathology |
3 |
|
cerebellar neoplasms - pathology - radiotherapy |
3 |
|
cerebellar neoplasms - therapy |
3 |
|
cerebral cortex - pathology |
3 |
|
cerebral thrombosis |
3 |
|
chemotherapy, adjuvant |
3 |
|
chickenpox |
3 |
|
childhood |
3 |
|
childhood acute lymphoblastic leukaemia |
3 |
|
childhood leukemia |
3 |
|
childhood solid tumors |
3 |
|
children (兒童) |
3 |
|
children cancer |
3 |
|
chimerism |
3 |
|
china - epidemiology |
3 |
|
chinese undergraduates |
3 |
|
cholelithiasis - blood - etiology - genetics |
3 |
|
chromosomes, human, pair 1 |
3 |
|
chromosomes, human, pair 12 - genetics |
3 |
|
chromosomes, human, pair 15 |
3 |
|
chromosomes, human, pair 19 |
3 |
|
chromosomes, human, pair 4 |
3 |
|
chromosomes, human, pair 5 |
3 |
|
chronic inflammatory demyelinating polyneuropathy |
3 |
|
clone cells |
3 |
|
coated materials, biocompatible - chemistry |
3 |
|
cognition disorders - diagnosis - etiology |
3 |
|
collagen |
3 |
|
collagen - administration & dosage - chemistry - pharmacology |
3 |
|
collagen - chemistry |
3 |
|
congenital factor vii deficiency |
3 |
|
core binding factor alpha 2 subunit |
3 |
|
cortical laminar necrosis |
3 |
|
cranial irradiation - adverse effects |
3 |
|
cranial irradiation - adverse effects - methods |
3 |
|
cross-cultural differences |
3 |
|
cross-sectional studies |
3 |
|
cystadenoma, papillary - diagnosis - ethnology - pathology |
3 |
|
deferasirox |
3 |
|
deferoxamine - therapeutic use |
3 |
|
dendritic cells - drug effects - pathology - physiology |
3 |
|
dexamethasone |
3 |
|
diabetes insipidus |
3 |
|
diamond-blackfan syndrome |
3 |
|
diffusion magnetic resonance imaging |
3 |
|
diffusion tensor mri |
3 |
|
diploidy |
3 |
|
disease-free survival |
3 |
|
dna, neoplasm - genetics |
3 |
|
dna-binding proteins - genetics |
3 |
|
dominance, cerebral - physiology |
3 |
|
dose fractionation |
3 |
|
dose-response relationship, radiation |
3 |
|
down syndrome - genetics |
3 |
|
down-regulation |
3 |
|
drug compounding |
3 |
|
dura mater |
3 |
|
dysarthria |
3 |
|
dyskeratosis congenita |
3 |
|
ear canal - pathology |
3 |
|
ear neoplasms - drug therapy - pathology |
3 |
|
embryonal sarcoma |
3 |
|
endocrinopathy |
3 |
|
endothelial microparticles |
3 |
|
ependymoma |
3 |
|
essential thrombocythaemia |
3 |
|
extracellular vesicles |
3 |
|
fanconi anaemia |
3 |
|
fish |
3 |
|
forced expiratory flow rates |
3 |
|
forced expiratory volume |
3 |
|
formalin |
3 |
|
foscarnet |
3 |
|
frontal lobe - pathology - radiation effects |
3 |
|
frontal lobe - radiation effects |
3 |
|
fungal infection |
3 |
|
gallstones |
3 |
|
gallstones - etiology - genetics |
3 |
|
ganciclovir |
3 |
|
gene frequency |
3 |
|
germ cell tumour |
3 |
|
germinoma |
3 |
|
germinomas |
3 |
|
gilbert disease - blood - etiology - genetics |
3 |
|
gilbert syndrome |
3 |
|
granulomatous disease, chronic - immunology |
3 |
|
gvhd |
3 |
|
haploidy |
3 |
|
haplotype frequency |
3 |
|
hearing loss |
3 |
|
hematopoietic stem cell transplant |
3 |
|
hemoglobin h - analysis - genetics |
3 |
|
hemoglobin h disease |
3 |
|
hemoglobinuria - blood - classification - genetics |
3 |
|
hemolytic-uremic syndrome |
3 |
|
hemolytic-uremic syndrome - microbiology |
3 |
|
hemorrhage - etiology |
3 |
|
hemorrhagic cystitis |
3 |
|
hepatitis |
3 |
|
hepatoblastoma - genetics - pathology |
3 |
|
hepatomegaly - etiology |
3 |
|
hhv 6 |
3 |
|
histocompatibility antigens class i - analysis |
3 |
|
histocompatibility antigens class ii - analysis |
3 |
|
hla |
3 |
|
hla gene frequency |
3 |
|
hla haplotype frequency |
3 |
|
human papillomavirus vaccine |
3 |
|
hyperdiploid |
3 |
|
image enhancement |
3 |
|
image processing, computer-assisted |
3 |
|
imaging |
3 |
|
imatinib mesylate |
3 |
|
immune-compromised host |
3 |
|
immunophenotype |
3 |
|
immunosuppression |
3 |
|
incidence |
3 |
|
individualism-collectivism |
3 |
|
inherited thrombophilic factors |
3 |
|
inhibitor |
3 |
|
inorganic chemistry |
3 |
|
intensive care |
3 |
|
interferon-gamma - pharmacology |
3 |
|
interleukin 12 |
3 |
|
interleukin-17 - biosynthesis - genetics |
3 |
|
international child health |
3 |
|
intracranial |
3 |
|
intrathecal |
3 |
|
iron |
3 |
|
iron chelation therapy |
3 |
|
iron chelator |
3 |
|
iron overload - complications - diagnosis |
3 |
|
iron overload - diagnosis - etiology |
3 |
|
jaundice |
3 |
|
jaundice - etiology - genetics |
3 |
|
jurkat cells |
3 |
|
juvenile pernicious anaemia |
3 |
|
kiaa0495 |
3 |
|
l-asparaginase |
3 |
|
l1 |
3 |
|
learning disorders - diagnosis - etiology |
3 |
|
leukemia, myelogenous, chronic, bcr-abl positive - genetics |
3 |
|
leukemia, myelomonocytic, chronic - genetics |
3 |
|
leukemia, promyelocytic, acute - complications - drug therapy |
3 |
|
leukemia, promyelocytic, acute - drug therapy - pathology |
3 |
|
life tables |
3 |
|
liver - chemistry - physiopathology |
3 |
|
liver - pathology |
3 |
|
liver diseases - complications - diagnosis |
3 |
|
liver function tests |
3 |
|
liver iron concentration |
3 |
|
liver neoplasms - genetics - pathology |
3 |
|
liver transplant |
3 |
|
liver tumour |
3 |
|
liver, mr |
3 |
|
logistic models |
3 |
|
long non-coding rna |
3 |
|
long-term complications |
3 |
|
lung - radiography |
3 |
|
lung diseases, obstructive - complications - radiography |
3 |
|
lung, air trapping |
3 |
|
lung, ct |
3 |
|
lung, function |
3 |
|
lupus erythematosus, systemic - pathology - physiopathology |
3 |
|
lymphocyte activation |
3 |
|
lymphocyte transfusion |
3 |
|
macrophage |
3 |
|
malignancy |
3 |
|
mediastinal neoplasms - genetics - pathology |
3 |
|
medical biochemistry |
3 |
|
medical education |
3 |
|
medulloblastoma - diagnosis - drug therapy - radiotherapy |
3 |
|
medulloblastoma - drug therapy - radiotherapy - surgery |
3 |
|
medulloblastoma - pathology |
3 |
|
medulloblastoma - pathology - radiotherapy |
3 |
|
medulloblastoma - therapy |
3 |
|
medulloblastoma survivors |
3 |
|
meningeal neoplasms - diagnosis |
3 |
|
mesenchymal hamartoma |
3 |
|
mesenchymal stem cell |
3 |
|
mesenchymal stem cell transplantation - instrumentation - methods |
3 |
|
mesenchymal stem cell transplantation - methods |
3 |
|
mesenchymal stem cells - chemistry - cytology - physiology |
3 |
|
mesenchymal stem cells - cytology - drug effects - metabolism |
3 |
|
mesenchymal stem cells - cytology - immunology |
3 |
|
mesenchymal stem cells - cytology - physiology |
3 |
|
mesenchymal stem cells - drug effects - immunology |
3 |
|
mesentery |
3 |
|
meta-analysis |
3 |
|
methotrexate - administration & dosage |
3 |
|
metoclopramide |
3 |
|
mice |
3 |
|
microencapsulation |
3 |
|
mitochondria |
3 |
|
molecular cytogenetics |
3 |
|
monosomy 7 |
3 |
|
msc |
3 |
|
multidisciplianry care |
3 |
|
multiple myeloma - diagnosis - pathology |
3 |
|
multivariate analysis |
3 |
|
mutation |
3 |
|
myeloma |
3 |
|
myeloperoxidase deficiency |
3 |
|
myeloproliferation |
3 |
|
myelosuppression |
3 |
|
myocardium - chemistry |
3 |
|
near-haploid |
3 |
|
necrosis |
3 |
|
neoplasm metastasis |
3 |
|
neoplasms |
3 |
|
neoplasms - metabolism - therapy |
3 |
|
neoplasms, germ cell and embryonal - radiotherapy |
3 |
|
nerve fibers, myelinated - drug effects - pathology - radiation effects |
3 |
|
neuroectodermal tumors, primitive - diagnosis |
3 |
|
nosocomial transmission |
3 |
|
oral mucositis |
3 |
|
organometallic chemistry |
3 |
|
orthotopic mouse model |
3 |
|
osteoblasts - cytology |
3 |
|
osteogenesis - drug effects - physiology |
3 |
|
osteogenesis - immunology |
3 |
|
osteogenic differentiation |
3 |
|
osteosarcoma |
3 |
|
osteosarcoma - drug therapy - epidemiology - pathology - surgery |
3 |
|
outbreak |
3 |
|
oxides - administration & dosage |
3 |
|
oxides - therapeutic use |
3 |
|
pain - etiology |
3 |
|
pancreas - chemistry |
3 |
|
pancreatic neoplasms - diagnosis - ethnology - pathology |
3 |
|
pancreatitis |
3 |
|
pancreatitis - chemically induced - drug therapy |
3 |
|
parietal lobe - pathology - radiation effects |
3 |
|
parietal lobe - radiation effects |
3 |
|
pelvic neoplasms - secondary |
3 |
|
peritoneal neoplasms - diagnosis |
3 |
|
phagocytes - physiology |
3 |
|
phagocytosis - immunology |
3 |
|
pik3ca |
3 |
|
pik3ca-related overgrowth spectrum |
3 |
|
pilot projects |
3 |
|
pineal gland |
3 |
|
plasmacytoma - secondary |
3 |
|
platelet count |
3 |
|
platelet-derived growth factor |
3 |
|
platelet-derived growth factor - pharmacology - therapeutic use |
3 |
|
pneumococcal infections |
3 |
|
pneumococcal infections - complications - microbiology |
3 |
|
pneumocystis carinii pneumonia |
3 |
|
precursor cell lymphoblastic leukemia-lymphoma - blood - drug therapy - epidemiology - pathology - radiotherapy |
3 |
|
predictive value of tests |
3 |
|
prematurity |
3 |
|
prevention |
3 |
|
primitive neuroectodermal tumour |
3 |
|
prognostic indicators |
3 |
|
prospective studies |
3 |
|
proto-oncogene proteins |
3 |
|
proto-oncogene proteins c-ets |
3 |
|
pulmonary ventilation |
3 |
|
q13) |
3 |
|
qualitative study |
3 |
|
questionnaires |
3 |
|
radiation injuries - diagnosis |
3 |
|
radiation tolerance |
3 |
|
radiotherapy dosage |
3 |
|
radiotherapy, adjuvant |
3 |
|
rank ligand - biosynthesis |
3 |
|
rapid |
3 |
|
rats |
3 |
|
reference values |
3 |
|
regenerative medicine - methods |
3 |
|
registry |
3 |
|
repressor proteins |
3 |
|
respiratory burst |
3 |
|
respiratory insufficiency - microbiology |
3 |
|
respiratory tract infections - microbiology |
3 |
|
reverse transcriptase polymerase chain reaction |
3 |
|
rheumatoid arthritis |
3 |
|
rhizopus |
3 |
|
salivary gland |
3 |
|
salvage therapy |
3 |
|
scoring system |
3 |
|
second cancer |
3 |
|
selective iga deficiency |
3 |
|
serotyping |
3 |
|
sex factors |
3 |
|
signal intensity threshold |
3 |
|
small bowel mesentery |
3 |
|
soft tissue neoplasms - diagnosis |
3 |
|
solid-cystic papillary tumor of the pancreas |
3 |
|
somatic mosaicism |
3 |
|
somatostatin |
3 |
|
somatostatin - therapeutic use |
3 |
|
spinal primitive neuroectodermal tumor |
3 |
|
spleen - chemistry |
3 |
|
splenomegaly - etiology |
3 |
|
spontaneous self-concept |
3 |
|
streptococcus pneumoniae |
3 |
|
streptococcus pneumoniae - classification - isolation and purification |
3 |
|
subcutaneous needle |
3 |
|
surgical excision |
3 |
|
survival |
3 |
|
systemic lupus erythematosus |
3 |
|
t cell dysfunction |
3 |
|
t helper 17 cells |
3 |
|
t(9 |
3 |
|
t-lymphocytes, regulatory - drug effects - immunology |
3 |
|
tel/aml1 fusion |
3 |
|
telomerase |
3 |
|
teratoma - drug therapy - pathology |
3 |
|
thalassemia - therapy |
3 |
|
thrombocytopenia - drug therapy - etiology |
3 |
|
thrombocytosis |
3 |
|
thrombocytosis - diagnosis |
3 |
|
thrombophilia - metabolism |
3 |
|
thrombopoiesis |
3 |
|
thymic neoplasm |
3 |
|
transcription factors - genetics |
3 |
|
translocation |
3 |
|
treatment |
3 |
|
tuberculosis - immunology |
3 |
|
tumour suppressor |
3 |
|
twenty statements test |
3 |
|
unnecessary procedures |
3 |
|
vaccination |
3 |
|
varicella |
3 |
|
vital capacity |
3 |
|
vitiligo |
3 |
|
von willebrand disease |
3 |
|
white-matter diffusion anisotrophy |
3 |
|
whole exome sequencing |
3 |
|
wiskott-aldrich syndrome |
3 |
|
zygomycosis |
3 |
|
3d speckle tracking |
2 |
|
3d speckle-tracking |
2 |
|
acupressure |
2 |
|
acute lymphobiastic leukaemia |
2 |
|
acute megakaryoblastic leukaemia |
2 |
|
acute megakaryoblastic leukaemia (amkl) |
2 |
|
adipocytes - cytology - drug effects - radiation effects |
2 |
|
adipogenesis - radiation effects |
2 |
|
adverse drug reactions |
2 |
|
aeromonas hydrophila - drug effects - growth & development - isolation & purification |
2 |
|
age of onset |
2 |
|
alkaline phosphatase - metabolism |
2 |
|
allogeneic hematopoietic stem cell transplantation |
2 |
|
allopurinol - therapeutic use |
2 |
|
alpha-thalassemia - genetics |
2 |
|
anemia - complications |
2 |
|
anemias |
2 |
|
animal cell |
2 |
|
animal experiment |
2 |
|
animal model |
2 |
|
animal tissue |
2 |
|
anthracycline |
2 |
|
anthracycline cardiotoxicity |
2 |
|
anthracyclines - adverse effects |
2 |
|
anthracyclines - adverse effects - therapeutic use |
2 |
|
anti-cd20 monoclonal antibody |
2 |
|
antibiotics, antineoplastic - adverse effects - therapeutic use |
2 |
|
antigens, cd - analysis |
2 |
|
antimetabolites - therapeutic use |
2 |
|
antineoplastic agents - pharmacology |
2 |
|
antiviral activity |
2 |
|
apde |
2 |
|
artepillin c |
2 |
|
arterial function |
2 |
|
arterial stiffness |
2 |
|
arteries |
2 |
|
arteries - physiopathology |
2 |
|
arthralgia - chemically induced |
2 |
|
asia, southeastern - epidemiology |
2 |
|
asian continental ancestry group - genetics |
2 |
|
asparaginase - metabolism |
2 |
|
atrial function |
2 |
|
autoimmune |
2 |
|
autologous hematopoietic stem cell transplantation |
2 |
|
barley |
2 |
|
base sequence |
2 |
|
benzoic acids - adverse effects - pharmacology |
2 |
|
beta-thalassaemia major |
2 |
|
beta-thalassemia - blood - physiopathology - ultrasonography |
2 |
|
beta-thalassemia - complications - drug therapy |
2 |
|
beta-thalassemia - complications - epidemiology - genetics |
2 |
|
beta-thalassemia - complications - physiopathology |
2 |
|
beta-thalassemia - diagnosis - drug therapy |
2 |
|
beta-thalassemia - drug therapy |
2 |
|
beta-thalassemia - ultrasonography |
2 |
|
beta-thalassemia major |
2 |
|
bicycle |
2 |
|
biopsy, needle |
2 |
|
bismuth |
2 |
|
bleomycin |
2 |
|
blood pressure - physiology |
2 |
|
blood transfusion |
2 |
|
bone and bones - drug effects - metabolism - radiation effects |
2 |
|
bone marrow |
2 |
|
bone marrow cells - cytology |
2 |
|
bone marrow cells - cytology - drug effects - radiation effects |
2 |
|
bone marrow transplant |
2 |
|
brachial artery - cytology - physiopathology |
2 |
|
burkitt lymphoma - genetics - mortality - therapy |
2 |
|
calcium - metabolism |
2 |
|
carbon monoxide |
2 |
|
carboxyfluorescein diacetate succinimidyl ester |
2 |
|
cardiac failure |
2 |
|
cardiac magnetic resonance imaging t2* (mri t2*) |
2 |
|
cardiac t2* |
2 |
|
cardiovascular disease |
2 |
|
cardiovascular diseases |
2 |
|
cardiovascular magnetic resonance |
2 |
|
cardiovascular parameters |
2 |
|
carotid arteries - physiopathology |
2 |
|
carvedilol |
2 |
|
case series |
2 |
|
cell differentiation - drug effects - radiation effects |
2 |
|
cell migration |
2 |
|
cell proliferation - drug effects - radiation effects |
2 |
|
cell therapy |
2 |
|
cell transformation, neoplastic |
2 |
|
central nervous system |
2 |
|
central nervous system neoplasms |
2 |
|
central nervous system tumor |
2 |
|
chelation protocol |
2 |
|
chelation therapy - adverse effects |
2 |
|
chelation therapy - methods |
2 |
|
chemotherapy regimen |
2 |
|
chickenpox vaccine - therapeutic use |
2 |
|
childhood leukaemia survivors |
2 |
|
china - epidemiology - ethnology |
2 |
|
cholelithiasis - epidemiology - etiology - genetics |
2 |
|
chorionic gonadotropin |
2 |
|
choroid plexus |
2 |
|
chromosome aberrations - genetics |
2 |
|
chromosome banding |
2 |
|
chromosome deletion |
2 |
|
chromosome inversion |
2 |
|
chromosomes, human, pair 11 |
2 |
|
chromosomes, human, pair 13 - genetics |
2 |
|
chromosomes, human, pair 17 - genetics |
2 |
|
chromosomes, human, pair 2 - genetics |
2 |
|
chromosomes, human, pair 22 - genetics |
2 |
|
chronic itp |
2 |
|
cisplatin |
2 |
|
clonal evolution |
2 |
|
coaching |
2 |
|
collaboration |
2 |
|
collaborative group |
2 |
|
color |
2 |
|
compliance |
2 |
|
controlled clinical trials as topic |
2 |
|
controlled study |
2 |
|
correlation analysis |
2 |
|
cyclophosphamide |
2 |
|
cytogenetic analysis |
2 |
|
cytometry |
2 |
|
deferasirox (dfra) |
2 |
|
deferiprone |
2 |
|
deferoxamine |
2 |
|
deferoxamine (dfo) |
2 |
|
deferoxamine - administration & dosage - adverse effects - therapeutic use |
2 |
|
deferoxamine - adverse effects - pharmacology |
2 |
|
deferoxamine(dfo) |
2 |
|
delivery tool |
2 |
|
diagnosis |
2 |
|
diarrhea |
2 |
|
diastole |
2 |
|
diastolic function |
2 |
|
diastolic wall strain |
2 |
|
differentiation |
2 |
|
dna |
2 |
|
dna primers |
2 |
|
down syndrome |
2 |
|
down syndrome - complications |
2 |
|
down's syndrome |
2 |
|
drug eruptions - etiology |
2 |
|
drug screening assays, antitumor |
2 |
|
drug selectivity |
2 |
|
drug therapy, combination |
2 |
|
dural sinus thrombosis |
2 |
|
ebv hemophagocytic syndrome |
2 |
|
echocardiography |
2 |
|
echocardiography, doppler - methods |
2 |
|
echocardiography, three-dimensional - methods |
2 |
|
efficacy |
2 |
|
electrogastrography |
2 |
|
endometrial stromal sarcoma |
2 |
|
endometriosis |
2 |
|
endothelium |
2 |
|
endothelium, vascular - physiopathology |
2 |
|
eosinophilia |
2 |
|
exercise echocardiography |
2 |
|
fetal diseases - genetics |
2 |
|
fluorometry |
2 |
|
gamma interferon |
2 |
|
ganoderma lucidum |
2 |
|
gastrointestinal |
2 |
|
gastrointestinal diseases - chemically induced |
2 |
|
gene deletion |
2 |
|
genetic modification |
2 |
|
genetic testing |
2 |
|
genotype-phenotype correlation |
2 |
|
gilbert alleles |
2 |
|
gilbert disease - complications - epidemiology - genetics |
2 |
|
glutathione |
2 |
|
graft-versus-host disease |
2 |
|
gram-negative bacterial infections - chemically induced - epidemiology |
2 |
|
haematology |
2 |
|
haemolysis |
2 |
|
heart diseases - diagnosis - etiology - prevention and control |
2 |
|
heart ventricles - ultrasonography |
2 |
|
hematologic diseases - complications |
2 |
|
hematologic neoplasms - complications |
2 |
|
hematology |
2 |
|
hepatomegaly |
2 |
|
hepatomegaly - complications - pathology - surgery |
2 |
|
herpesvirus |
2 |
|
histiocytosis, sinus - complications - congenital |
2 |
|
human dendritic cell |
2 |
|
hydrops fetalis |
2 |
|
hydrops fetalis - genetics - prevention & control |
2 |
|
hyperbilirubinemia |
2 |
|
hypoxia |
2 |
|
immunomodulation |
2 |
|
infancy |
2 |
|
infliximab |
2 |
|
influenza vaccines - therapeutic use |
2 |
|
inhibitory concentration 50 |
2 |
|
integrated experiential training |
2 |
|
interleukin 17 |
2 |
|
interleukin 2 |
2 |
|
intervention strategies |
2 |
|
intima-media thickness |
2 |
|
iron chelating agents - administration & dosage - adverse effects - therapeutic use |
2 |
|
iron chelating agents - administration and dosage - therapeutic use |
2 |
|
iron chelating agents - adverse effects - pharmacology |
2 |
|
iron load |
2 |
|
iron overload - drug therapy |
2 |
|
iron overload - drug therapy - etiology |
2 |
|
iron overload - drug therapy - microbiology |
2 |
|
iron-overload |
2 |
|
irradiation |
2 |
|
isochromosomes - genetics |
2 |
|
juvenile myelomonocytic leukaemia |
2 |
|
keratolytic agents - pharmacology |
2 |
|
ketamine |
2 |
|
kinetics |
2 |
|
klebsiella infections - chemically induced - epidemiology |
2 |
|
klebsiella pneumoniae |
2 |
|
klebsiella pneumoniae - drug effects - growth & development - isolation & purification |
2 |
|
leukemia, lymphocytic, acute |
2 |
|
leukemia, lymphocytic, acute - drug therapy - mortality |
2 |
|
leukemia, lymphoid - drug therapy - pathology |
2 |
|
leukemia, megakaryoblastic, acute - complications |
2 |
|
leukemia, megakaryoblastic, acute - genetics |
2 |
|
leukemia, monocytic, acute - genetics - therapy |
2 |
|
leukemia, myelomonocytic, chronic - pathology |
2 |
|
leukemia-lymphoma, adult t-cell - genetics - mortality - therapy |
2 |
|
leukopoiesis |
2 |
|
liver - chemistry - pathology |
2 |
|
low grade glioma |
2 |
|
lymphoblastic leukaemia |
2 |
|
lymphoid leukemic cells |
2 |
|
lymphoma |
2 |
|
lymphoma, extranodal nk-t-cell - pathology - therapy |
2 |
|
magnetic resonance imaging - methods |
2 |
|
marine algae extract |
2 |
|
marrow stromal stem cells |
2 |
|
medicine & public health |
2 |
|
megakaryoblastic transformation |
2 |
|
megakaryopoiesis |
2 |
|
melatonin |
2 |
|
mesenchymal stem cell transplantation |
2 |
|
mesenchymal stem cells (mscs) |
2 |
|
mesenchymal stem cells - cytology |
2 |
|
mesenchymal stem cells - cytology - drug effects - radiation effects |
2 |
|
mesenchymal stromal cells |
2 |
|
mesoderm - metabolism |
2 |
|
midazolam |
2 |
|
mir-340-5p |
2 |
|
models, biological |
2 |
|
molecular sequence data |
2 |
|
monosaccharide transport proteins - genetics |
2 |
|
mrp |
2 |
|
multidisciplinary |
2 |
|
multiple myeloma |
2 |
|
multi‐disciplinary team |
2 |
|
myeloid-lymphoid leukemia protein |
2 |
|
myocardial deformation |
2 |
|
myocardial fibrosis |
2 |
|
myocardial iron load |
2 |
|
myocardial stiffness |
2 |
|
myocardial strain gradient |
2 |
|
neoplasm recurrence, local - epidemiology |
2 |
|
neoplasm staging |
2 |
|
neuroblastoma - genetics - pathology |
2 |
|
neutropaenic colitis |
2 |
|
non-hsct |
2 |
|
nose/pathology |
2 |
|
nuclear proteins - genetics |
2 |
|
oncogene proteins - genetics |
2 |
|
oncogene proteins, fusion - genetics |
2 |
|
oral arsenic |
2 |
|
osteogenesis - drug effects - radiation effects |
2 |
|
osteoporosis |
2 |
|
osteoprotegerin |
2 |
|
ovary |
2 |
|
overall survival |
2 |
|
oxidative stress |
2 |
|
p-erk1/2 |
2 |
|
paediatric mds |
2 |
|
paediatric oncology |
2 |
|
parents |
2 |
|
pediatric apl |
2 |
|
pediatric brain tumor survivors |
2 |
|
pediatric cancer survivors |
2 |
|
perinatal hiv |
2 |
|
piperazines - pharmacology |
2 |
|
platelet dysfunction |
2 |
|
poliovirus vaccines - therapeutic use |
2 |
|
polycythaemia vera |
2 |
|
polysaccharides |
2 |
|
positive feedback |
2 |
|
precursor b-cell lymphoblastic leukemia-lymphoma - genetics |
2 |
|
precursor cell lymphoblastic leukemia-lymphoma - genetics - mortality - therapy |
2 |
|
precursor cell lymphoblastic leukemia-lymphoma - genetics - pathology |
2 |
|
pregnancy |
2 |
|
premenarche |
2 |
|
prevalence |
2 |
|
primary care |
2 |
|
proliferation |
2 |
|
proplatelet |
2 |
|
proto-oncogenes |
2 |
|
psycho-oncology |
2 |
|
pyridones - administration & dosage - adverse effects - therapeutic use |
2 |
|
pyridones - adverse effects - pharmacology |
2 |
|
pyrimidines - pharmacology |
2 |
|
radiation injuries - prevention & control |
2 |
|
renal tubular dysfunction |
2 |
|
retinoic acid |
2 |
|
rituximab |
2 |
|
rna-binding proteins - genetics |
2 |
|
rosai-dorfman disease |
2 |
|
safety |
2 |
|
salmonella |
2 |
|
sdf-1 |
2 |
|
sea deletion |
2 |
|
sedation |
2 |
|
sepsis |
2 |
|
sequence deletion - physiology |
2 |
|
serotonin |
2 |
|
serous borderline |
2 |
|
serum electrolyte |
2 |
|
serum ferritin (sf) |
2 |
|
serum ferritin(sf) |
2 |
|
sinus histiocytosis with massive lymphadenopathy |
2 |
|
skeletal complication |
2 |
|
speckle tracking echocardiography |
2 |
|
steroid dependent |
2 |
|
steroid refractory |
2 |
|
strain |
2 |
|
stromal cells - metabolism |
2 |
|
stromal suppression |
2 |
|
survivorship |
2 |
|
systemic lupus erythematosus (sle) |
2 |
|
systole |
2 |
|
t/nk cell lymphoma |
2 |
|
target-killing |
2 |
|
tetrazolium salts - pharmacology |
2 |
|
thalassemia - drug therapy - microbiology |
2 |
|
thalassemia intermedia |
2 |
|
thalassemia major |
2 |
|
thrombocytopenia - complications |
2 |
|
titin |
2 |
|
tpo |
2 |
|
transcription factors |
2 |
|
transient abnormal myelopoiesis |
2 |
|
transient myeloproliferative disease |
2 |
|
transplant complication |
2 |
|
transplantation immunology |
2 |
|
tretinoin - pharmacology |
2 |
|
triazoles - adverse effects - pharmacology |
2 |
|
trisomy |
2 |
|
trisomy 21 |
2 |
|
tumor lysis syndrome - mortality - prevention and control |
2 |
|
tumour biology |
2 |
|
ultrasonography |
2 |
|
urate oxidase - adverse effects - therapeutic use |
2 |
|
vascular resistance - physiology |
2 |
|
vasodilation |
2 |
|
ventricles |
2 |
|
ventricular dysfunction, left - chemically induced - physiopathology - ultrasonography |
2 |
|
ventricular dysfunction, left - complications - physiopathology |
2 |
|
ventricular function, left |
2 |
|
ventricular mechanics |
2 |
|
ventricular remodeling |
2 |
|
ventricular rotation |
2 |
|
ventricular torsion |
2 |
|
vincristine |
2 |
|
vincristine - pharmacology |
2 |
|
viral gastroenteritis |
2 |
|
virus diseases - prevention and control |
2 |
|
vomiting |
2 |
|
x-linked lymphoproliferative disease |
2 |
|
x-rays |
2 |
|
xenograft |
2 |
|
xiap |
2 |
|
young cancer patients |
2 |
|
α-globin gene deletions |
2 |
|
α-thalassemia |
2 |
|
β-thalassaemia |
2 |
|
acute lymphoblastic leukemia |
1 |
|
adamts13 |
1 |
|
adrenal |
1 |
|
adrenal gland neoplasms - complications - genetics - pathology |
1 |
|
aml |
1 |
|
aml-1 |
1 |
|
aml-lbc (aml with a low blast count) |
1 |
|
anemia, refractory, with excess of blasts - genetics - pathology |
1 |
|
anticancer |
1 |
|
arginase |
1 |
|
arsenic trioxide |
1 |
|
beta-glucans - administration and dosage - pharmacokinetics - pharmacology |
1 |
|
biological products - administration and dosage |
1 |
|
birds |
1 |
|
bone marrow - pathology |
1 |
|
bone marrow cells - cytology - drug effects |
1 |
|
bone marrow microenvironment |
1 |
|
cancer survivor |
1 |
|
carcinoma, small cell - complications - genetics - pathology |
1 |
|
cardiac siderosis |
1 |
|
cardiomyopathy |
1 |
|
cardiovascular mr |
1 |
|
cd9 |
1 |
|
child health |
1 |
|
child health care |
1 |
|
children and adolescents |
1 |
|
chromosomes, human, pair 12 |
1 |
|
chromosomes, human, pair 21 |
1 |
|
chromosomes, human, pair 7 |
1 |
|
cisplatin (順鉑) |
1 |
|
cisplatin - pharmacology |
1 |
|
clinical status |
1 |
|
clone cells - pathology |
1 |
|
coagulants - therapeutic use |
1 |
|
coagulation factor concentrate |
1 |
|
cxcr4 |
1 |
|
cxcr7 |
1 |
|
cytogenetic |
1 |
|
cytokine |
1 |
|
danggui buxue tang (dbt) |
1 |
|
danshen (salvia miltiorrhiza) |
1 |
|
daunorubicin (柔紅霉素) |
1 |
|
daunorubicin - pharmacology |
1 |
|
dectin-1 |
1 |
|
deletion 13q |
1 |
|
delivery of health care |
1 |
|
dendritic cells |
1 |
|
disease activity |
1 |
|
disease outbreaks |
1 |
|
down syndrome - diagnosis |
1 |
|
electron microscopy |
1 |
|
erythroblasts |
1 |
|
erythroblasts - pathology - ultrastructure |
1 |
|
erythrocyte transfusion |
1 |
|
factor ix - therapeutic use |
1 |
|
factor viii |
1 |
|
factor viii - therapeutic use |
1 |
|
family medicine |
1 |
|
fever - etiology - genetics - pathology |
1 |
|
global health governance |
1 |
|
growth |
1 |
|
haemangioma |
1 |
|
haemophilia |
1 |
|
haemophilia b |
1 |
|
health care quality |
1 |
|
health service |
1 |
|
healthcare burden |
1 |
|
healthcare resources |
1 |
|
hematopoiesis |
1 |
|
hemiparesis |
1 |
|
hemoglobinometry |
1 |
|
hemophilia a |
1 |
|
hemophilia a - epidemiology - physiopathology - therapy |
1 |
|
hemophilia b - epidemiology - physiopathology - therapy |
1 |
|
hiv infections |
1 |
|
hiv infections - epidemiology |
1 |
|
homing |
1 |
|
hydroxyurea (羥基脲) |
1 |
|
hydroxyurea - pharmacology |
1 |
|
immune |
1 |
|
immune deficiency |
1 |
|
immune homeostasis |
1 |
|
immune system - drug effects |
1 |
|
immune tolerance |
1 |
|
infant, premature |
1 |
|
infectious diseases |
1 |
|
influenza a virus, h5n1 subtype |
1 |
|
influenza in birds - epidemiology |
1 |
|
interleukin-33 |
1 |
|
international cooperation |
1 |
|
ischemic attack, transient - blood - diagnosis - therapy |
1 |
|
kasabach merritt phenomenon |
1 |
|
kidney |
1 |
|
leukemia, myeloid - diagnosis - genetics |
1 |
|
leukemia, myeloid, acute - complications - therapy |
1 |
|
leukemoid reaction - diagnosis - genetics |
1 |
|
loss of heterozygosity |
1 |
|
macrophages |
1 |
|
marrow transplantation |
1 |
|
mds |
1 |
|
mechanisms |
1 |
|
megakaryocytopoiesis |
1 |
|
mesenchymal stem cell (間充質干細胞) |
1 |
|
mesenchymal stem cells - cytology - drug effects |
1 |
|
metanephric adenofibroma |
1 |
|
mitochondria - pathology - ultrastructure |
1 |
|
mitochondrial cytopathy |
1 |
|
mortality |
1 |
|
mosaicism |
1 |
|
mscs |
1 |
|
mtor inhibitor |
1 |
|
multi-directional |
1 |
|
myelodysplastic syndrome (mds) |
1 |
|
myelopoiesis - genetics |
1 |
|
natural killer cells |
1 |
|
neoplasms - drug therapy - pathology |
1 |
|
neurologic examination |
1 |
|
newborn piglet |
1 |
|
nurse training |
1 |
|
ornithine transcarbamylase |
1 |
|
pediatric cancers |
1 |
|
pediatrician |
1 |
|
platelet aggregation |
1 |
|
pneumococcal infection |
1 |
|
primitive tumour |
1 |
|
propolis |
1 |
|
prothrombin complex concentrate |
1 |
|
public health administration |
1 |
|
pyrexia of unknown origin |
1 |
|
radix angelicae sinensis |
1 |
|
radix astragali |
1 |
|
refractory anemia with ringed sideroblasts (rars |
1 |
|
regulatory b cells |
1 |
|
remission, spontaneous |
1 |
|
retinoblastoma |
1 |
|
severe acute respiratory syndrome - epidemiology |
1 |
|
sovereignty |
1 |
|
surgical risk |
1 |
|
survival rate |
1 |
|
survivorship program |
1 |
|
tanshinone iia |
1 |
|
tel |
1 |
|
thromboembolism |
1 |
|
thrombopoietin |
1 |
|
thrombotic thrombocytopenic purpura |
1 |
|
thromboxane b 2 |
1 |
|
topotecan (拓撲替康) |
1 |
|
topotecan - pharmacology |
1 |
|
transient erythroblastopenia of childhood |
1 |
|
translocations |
1 |
|
tuberous sclerosis |
1 |
|
vascular malformation |
1 |
|
vwf-cleaving protease |
1 |
|
who |
1 |
|
world health |
1 |
|
world health organization |
1 |
|
β-glucan |
1 |
